San Francisco startup Construction Therapeutics can be working on an oral, when-day-to-day GLP-1 drug named GSBR-1290—the drug surpassed Wall Road’s expectations in June each time a mid-phase study confirmed average weight loss of all around six% and it ideas to get started on One more mid-stage demo towards the top of this year—that founder